|
Press Releases |
|
|
|
Thursday, September 17, 2020 |
|
Dyadic Announces Collaboration with Jiangsu Hengrui Medicine for Biologic Drug Development |
Dyadic International, Inc. ("Dyadic" or the "Company") (NASDAQ:DYAI), a global biotechnology company focused on further applying its proprietary C1 gene expression platform to accelerate development, lower production costs and improve the performance of biologic vaccines and drugs at flexible commercial scales, today announced collaboration with Jiangsu Hengrui Medicine Co., Ltd. ("Hengrui") (SSE:600276) to apply Dyadic's C1 technology to the development of selected Hengrui biologic drug(s). more info >> |
|
Dyadic宣布與江蘇恆瑞醫藥合作開發生物藥物 |
全球生物技術公司Dyadic 國際股份有限公司(以下簡稱“ Dyadic”或“公司”)(納斯達克股票代碼:DYAI)一直致力於改進和應用其專有的C1基因表達平台,加速生物疫苗、藥物和其他生物製品的開發、降低生產成本並改善其性能,具有靈活的商業規模。今天宣布與江蘇恆瑞醫藥有限公司(“恆瑞”)(SSE:600276)合作,將Dyadic的C1技術應用於選定的恆瑞生物藥物的開發中。 more info >> |
|
Dyadic宣布与江苏恒瑞医药合作开发生物药物 |
全球生物技术公司Dyadic 国际股份有限公司(以下简称“ Dyadic”或“公司”)(纳斯达克股票代码:DYAI)一直致力于改进和应用其专有的C1基因表达平台,加速生物疫苗、药物和其他生物制品的开发、降低生产成本并改善其性能,具有灵活的商业规模。今天宣布与江苏恒瑞医药有限公司(“恒瑞”)(SSE:600276)合作,将Dyadic的C1技术应用于选定的恒瑞生物药物的开发中。 more info >> |
|
Tuesday, March 31, 2020 |
|
Dyadic宣布與藥明生物達成非排他性研究許可協議 |
全球生物技術公司Dyadic國際股份有限公司(以下簡稱“ Dyadic”或“公司”)(納斯達克股票代碼:DYAI)一直致力於改進和應用其專有的C1基因表達平台,加速生物疫苗、藥物和其他生物製品的開發、降低生產成本並改善其性能,具有靈活的商業規模。公司今天宣布,它已與全球領先的開放式生物製品技術平台公司及醫藥合同定制研發生產企業(CDMO)——藥明生物攜手,共同進行非排他性研究合作。 more info >> |
|
Dyadic宣布与药明生物达成非排他性研究许可协议 |
全球生物技术公司Dyadic国际股份有限公司(以下简称“ Dyadic”或“公司”)(纳斯达克股票代码:DYAI)一直致力于改进和应用其专有的C1基因表达平台,加速生物疫苗、药物和其他生物制品的开发、降低生产成本并改善其性能,具有灵活的商业规模。公司今天宣布,它已与全球领先的开放式生物制品技术平台公司及医药合同定制研发生产企业(CDMO)——药明生物携手,共同进行非排他性研究合作。 more info >> |
|
Monday, March 30, 2020 |
|
Dyadic Announces Nonexclusive Research License with WuXi Biologics |
Dyadic International, Inc. (NASDAQ:DYAI) today announced that it has entered into a nonexclusive research collaboration with WuXi Biologics, a leading global open-access biologics technology platform company and Contract Development and Manufacturing Organization. more info >> |
|
Thursday, May 9, 2019 |
|
Dyadic攜手印度血清研究所 Serum研發和製造 全球廣泛使用且可負擔得起的抗體產品和疫苗 |
Dyadic國際股份有限公司(以下簡稱''Dyadic'')(納斯達克:DYAI)專注於深入改善和應用旗下專利級C1基因表達平台來加速生物疫苗、藥物和其他生物產品的開發進程,降低生產成本,改善效用,推動靈活的商用普及。 more info >> |
|
Dyadic携手印度血清研究所 Serum研发和制造 全球广泛使用且可负担得起的抗体产品和疫苗 |
Dyadic国际股份有限公司(以下简称''Dyadic'')(纳斯达克:DYAI)专注于深入改善和应用旗下 专利级C1基因表达平台来加速生物疫苗、药物和其他生物产品的开发进程,降低生产成本,改善效用,推动灵活的商用普及。 more info >> |
|
Dyadic and Serum Institute of India to Develop and Manufacture Globally Affordable and Accessible Antibody Products and Vaccines |
Dyadic International, Inc. is pleased to announce a research and commercialization collaboration with Serum Institute of India Pvt., Ltd, one of the world's largest vaccine manufacturers, to develop and manufacture up to twelve antibodies and vaccines using Dyadic's C1 gene expression platform. more info >> |
|
|
|
|
|
|
|
|
Latest Press Releases |
|
三菱重工、新たな防衛輸送用「機動舟艇」に搭載するウォータージェット推進装置の供給へ
Nov 22, 2024 11:45: JST
|
|
|
Jacobson Pharma Announces FY2025 Interim Results
Nov 22, 2024 10:00 HKT/SGT
|
|
|
雅各臣公佈二零二五財年中期業績 持續經營業務溢利飈升44.2%
Nov 22, 2024 10:00 HKT/SGT
|
|
|
Mailbird Expands to Mac: Popular Windows Email Client Launches Much-Anticipated Mac App
Nov 22, 2024 10:00 HKT/SGT
|
|
|
DesignInspire opens on December 5, with free admission for the public
Nov 22, 2024 09:00 HKT/SGT
|
|
|
アレス・マネジメント、東京オフィス開設でアジア事業を拡充
Nov 22, 2024 09:00: JST
|
|
|
Yahoo Finance Invest Asia 2024 - Disrupting Finance: Innovations Shaping The Future
Nov 22, 2024 08:50 HKT/SGT
|
|
|
NaaS Q3 2024 Recap: Strategic Shifts and Tech Innovations for Growth
Nov 21, 2024 22:59 JST
|
|
|
GMG Unveils SUPER G(R): A Game-Changing Graphene Solution for the Lithium-Ion Battery Industry
Nov 21, 2024 21:29 HKT/SGT
|
|
|
neurocare Group AG Welcomes Kevin Reeder as Chief Financial Officer
Nov 21, 2024 21:20 HKT/SGT
|
|
|
Experience the Power of Movement: Jin Pilates Brings Singapore's First Garuda Studio for Dynamic, Holistic Wellness
Nov 21, 2024 21:00: JST
|
|
|
Experience the Power of Movement: Jin Pilates Brings Singapore's First Garuda Studio for Dynamic, Holistic Wellness
Nov 21, 2024 20:19 HKT/SGT
|
|
|
透雲生物萊茵衣藻獲國家衛健委新用途許可
Nov 21, 2024 19:51 HKT/SGT
|
|
|
透云生物莱茵衣藻获国家卫健委新用途许可
Nov 21, 2024 19:33 HKT/SGT
|
|
|
SGX-Listed Mooreast Appoints Norwegian Eirik Ellingsen as CEO to Drive Growth in Global Floating Offshore Wind Market
Nov 21, 2024 19:00 HKT/SGT
|
|
|
|
More News >> |
|
|
|
|
|